{'fraction_non_alphanumeric': 0.026948542223254733, 'fraction_numerical': 0.013629147791071359, 'mean_word_length': 5.370991613221509, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database

The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using “TargetMine,” a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the “survival discharge.” Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients.

The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using "TargetMine," a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the "survival discharge." Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis

INTRODUCTION
Despite advances in treatment, cardiac arrest still results in a high mortality rate. In the United States alone, more than 550,000 cardiac arrest cases are reported annually, with the survival discharge rate being only 12% and 24.8% for out-ofhospital and in-hospital patients, respectively (The American Heart Association, 2013). Considering the increase in aging population, the number of cardiac arrest patients is also expected to increase; hence, there is an urgent need to develop a treatment that improves the prognosis of patients suffering cardiac arrest.
Cardiac arrest damages heart functions and those of other organs. Particularly, it results in myocardial dysfunction at the early stages after resuscitation; moreover, circulation becomes very unstable (Jentzer et al., 2015). Myocardial dysfunction is associated with early death, and if improvement in cardiac function cannot be achieved within 24 h, conditions such as multiple organ failure, which have poor prognosis, are known to occur (Laurent et al., 2002). Therefore, normalization of hemodynamics is very important for improving the prognosis after cardiac arrest.
In recent years, drug repositioning (DR) has attracted attention as a strategy of drug development. In the DR approach, new pharmacological effects of already approved drugs with known safety for humans are identified. These drugs are then used as new therapeutic agents for other diseases according to the identified effect (Ashburn and Thor, 2004;Zamami et al., 2017). The number of new drugs introduced in the market is decreasing yearly because the development of new drugs is expensive and time-consuming (Reuters, 2011). The main advantage of using the DR approach is that it can reduce drug development time and cost. Moreover, it reduces the risk of development failure due to unintended adverse effects and pharmacokinetic problems in the clinical trial stage. Various types of big data are now available, and utilization of these data can be highly useful for the DR approach. We anticipate that DR can contribute to the development of therapeutic agents that improve prognosis of cardiac arrest patients.
One such big data in the field of life science is the drug discovery science database. It includes a wide variety of information such as chemical structures, physical properties, pharmacological actions, and genes related to diseases. TargetMine has been developed by the National Institutes of Biomedical Innovation, Health and Nutrition (Japan). It integrates more than 30 databases on bioinformatics worldwide (Chen et al., 2016). It can be used to identify related diseases and drugs based on a specific gene. Similarly, a representative medical information big data for the medical sciences is Japan Medical Data Center (JMDC) Claims Database. It is a database of 5.6 million cases collected from Japan's health insurance association, which includes information on the diagnosis of diseases and prescription medicines and reflects the actual clinical practices. Using these databases, it is possible to evaluate the efficacy and safety of drugs in the realworld setting (Sugiyama et al., 2016;Yokoyama et al., 2018).
It is difficult to develop an experimental drug for cardiac arrest due to the urgency of treatment and ethical problems. However, we can use the DR approach by utilizing drug discovery science databases and medical information databases to identify candidate drugs expected to be effective in humans. Therefore, in this study, we aimed to search for drugs that can improve the survival rate of cardiac arrest patients using drug discovery tools and large-scale medical databases through the DR approach.

Extraction of Candidate Drugs by Targetmine
TargetMine internally integrates and combines various data from around the world. It is possible to use it for drug development by simultaneously specifying conditions such as target genes, proteins, and pharmacological actions, and thus simplifying complicated tasks. Compared with other data warehousing tools, TargetMine has simpler operation, and users can collect and prioritize information quickly and efficiently without the need for special programming skills (Chen et al., 2011;Chen et al., 2016). The occurrence of cardiac arrest causes systemic circulatory failure and hypoxia. Therefore, we focused our literature search on vasodilators because of their use in maintaining circulation after resumption of heart functioning (Yuuki et al., 1991). In this study, we used Anatomical Therapeutic Chemical Classification System (ATC) codes (widely used as a method to classify medicines according to efficacy, site of action, target organ, and chemical characteristics) as an extraction method of candidate drugs. We searched for pharmaceutical ingredients with an ATC code associated with vasodilator effect (Supplementary Table  1). TargetMine is a comprehensive tool and is suitable for this study because it can be used to extract information on drugs showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients.
Keywords: cardiac arrest, drug repositioning, claims database, drug discovery tool, vasodilator with pharmacological actions that correspond to specific ATC classifications.

Analysis of Large-Scale Medical Information
The claims database used in analysis was provided by the Japan Medical Data Center (JMDC), which includes approximately 3 million cases (as of November 2015) of receipt information. Information from medical hospital receipts, Diagnosis Procedure Combination (DPC) receipts, medical out-ofhospital receipts, and dispensing receipts was integrated. It was possible to obtain information, including disease name, medical treatment, and the dispensed items, from the insurance documents ( Supplementary Table 2-8). Moreover, since a unique ID is given to each participant, if one patient visits multiple medical institutions, it is possible to trace a series of processes from the occurrence of a disease to its convergence. Nevertheless, since all data are highly encrypted unlinkable anonymized information, it is not possible to identify an individual. The receipt dataset used in this study is provided in seven files: "patient information, " "receipt information," "facility information, " "doctor information," "injury information, " "pharmaceutical information, " and "medical treatment information. " The items contained in each file and their contents are shown in Supplementary Tables 2, 3, 4, 5, 6, 7, and 8. It should be noted that the diagnostic names in this dataset are used by the WHO for referring to causes of death and disease. The classification was based on the 10th edition of "International Statistical Classification of Diseases and Related Health Problems" (ICD-10). Drugs were classified according to the Anatomical Therapeutic Chemical Classification System (ATC classification) developed by the European Pharmaceutical Market Research Association (EphMRA). From January 2005 to May 2014, patients with the following (ICD-10) codes were classified as cardiac arrest patients (n = 2,546): I469 for cardiac arrest, I472 for pulseless ventricular tachycardia, I490 for transient ventricular fibrillation; and Japan specific medical action codes: J046 for non-thoracotomy heart massage, J047 for counter shock. Among these patients, those with traumatic cardiac arrest or <18 years of age or unconfirmed diagnosis or having missing data were excluded. Finally, 2,227 patients were included in the study. Cardiac arrest date was defined as the date at which the diagnosis of cardiac arrest was started; if the diagnosis date was unknown, the date on which the practice for cardiac arrest was performed was used. If multiple cardiac arrests occurred during the study period, the first date was taken as the patient's cardiac arrest date. We used the presence or absence of "the fee for providing treatment information at discharge" in claim data to define survival discharge. Patients who were charged this fee within 1 year from the day of cardiac arrest were defined as survival discharge patients. The data were processed using Microsoft Access 2013, and the information contained in the seven files described above was linked based on the patient ID. Because data about "birth date, " "join date," "JMDC data start date, " and "medical treatment date" could not be obtained, these dates were all set to the first day of that month. In addition, "the withdrawal date" and "JMDC data end date" were set to the last day of that month. In case the "medical care start date," the "prescription date of medicine, " or the "treatment date" were blank, the "consultation date" was used instead.

Narrowing Down Candidate Drugs
First, the drugs that were not currently approved in Japan were excluded. Parenteral administration suitable for the the patients with cardiac arrest because of they suffer from sever condition and are unconscious. Therefore, the drugs for which no injectable form was available were excluded. Subsequently, information of drugs administered within 1 month after cardiac arrest was extracted from 2,227 cardiac arrest cases identified as target patients. Of these, drugs administered in ≤10 patients were excluded as statistically reliable results could not be obtained when the number of patients was very small. The correlation between the administration of the candidate drugs and the survival discharge within 1 year was analyzed by logistic regression analysis. The administration of each candidate drug (diltiazem, disopyramide, flecainide, verapamil, isosorbide nitrate, nicardipine, and nitroglycerin) within 1 month from the cardiac arrest date was set as the explanatory variable, and the survival discharge within 1 year from the cardiac arrest date was set as the objective variable (Figure 1). The adjusted odds ratios (ORs) were calculated for the drugs showing a significant relationship with survival discharge in simple logistic regression analysis. The covariates used for the adjustment are shown n Supplementary Table 9.

Statistical Analysis
Continuous variables are presented as the mean ± standard deviation (SD) and categorical variables by using frequencies and percentages. To compare the effects of administration of each drug on survival discharge, simple logistic regression was performed with administration of diltiazem, disopyramide, flecainide, verapamil, isosorbide dinitrate, nicardipine, and nitroglycerin as covariates (Table 3). Isosorbide dinitrate, nitroglycerin, and nicardipine were divided into two groups based on the presence or absence of administration. Standardized mean differences (Tables 4, 5, 6) were calculated after adjusting each covariate using the inverse probability of treatment weighting (IPTW) method, and the variation of the covariates in both groups was examined. Using the IPTW method, adjusted ORs were calculated for comparing the rates of survival discharge between the two groups ( Table 7). Analyses were performed using R statistical software version 3.1.2., and statistical significance was defined as a p < 0.05.

Ethics Statement
This study was carried out in accordance with the recommendations of the Ethical Guidelines for Epidemiological Research by the Ministry of Health, Labour and Welfare. The protocol was approved by the ethics committees of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital (no. 105056). One cannot identify individuals from JMDC's claims database because all personal data including names are deleted and converted to an ID that cannot be linked with any personal information. Since this study was an observational study with anonymized information, no treatment intervention, and no collection of human samples, the requirement of obtaining informed consent was waived by the ethics committee.
Of these 165 candidate drugs, 39 were excluded, including those not either approved in Japan or those for which no injectable form was available. After further shortlisting for the drugs administered within 1 month from the day of cardiac arrest, 11 drugs were obtained. Finally, after exclusion of drugs that were used by ≤10 patients and those included in statistical analysis as covariates, seven drugs were shortlisted as the drug candidates for this study. The names and frequencies of drug administration of each drug are shown in Table 2, and the process of data extraction for drugs is shown in Figure 2.
Propensity score matching was performed to minimize patient background bias in the treatment and non-treatment groups. Standardized effects of each covariate before and after adjustment using the IPTW method are shown in Tables 4, 5, 6. The values of standardized effect decreased after adjustment compared with the values before adjustment, and the patient background bias was uniform. The adjusted odds ratios after adjustment with the IPTW method were as follows: isosorbide dinitrate, 3.35 (95% CI = 1.79-6.26); nitroglycerin, 5.44 (95% CI = 3.06-9.68); and nicardipine, 4.58 (95% CI = 2.53-8. 28) ( Table 7). These findings suggest that the survival discharge rate was significantly high in all three treatment groups.

DISCUSSION
Even after matching on covariates using propensity scores, the odds ratios for survival discharge within 1 year after cardiac arrest were significantly high in each of the isosorbide dinitrate, nitroglycerin, and nicardipine administration groups. This indicated that all three drugs improved the survival rate on hospital discharge.
To date, no large-scale clinical studies demonstrating the efficacy of nitroglycerin, isosorbide dinitrate, and nicardipine in cardiac arrest patients have been reported. However, some case reports were published reporting resuscitation being achieved by the administration of nitroglycerin in refractory cardiac arrest (Ward and Reid, 1984;Osada et al., 2000;Stefaniotou et al., 2014). Moreover, it was reported that acute coronary syndrome (ACS), which occurs after resuscitation from cardiac arrest, and cardiac arrest caused by ACS were improved by the administration of isosorbide dinitrate (Heming et al., 2010;Manzo-Silberman et al., 2010). In animal experiments using the heart of a paralyzed rat, nicardipine administration significantly improved blood flow in ischemic state (Tachibana, 1990;Mitchell et al., 1992).
Nitrate drugs, such as nitroglycerin and isosorbide dinitrate, stimulate guanylate cyclase in vascular smooth muscle cells via nitrogen oxide. At low doses, nitrates dilate the vessels in the venous system and at high doses dilate the arterial system vessels to reduce resistance. They provide stress relief (by pulmonary capillary pressure reduction) and afterload relief (by mild elevation of cardiac output and decrease in peripheral vascular resistance). Moreover, nitrates are widely used in heart failure caused by ischemic heart disease for their coronary artery dilation effect.
FIGURE 1 | Timeline of claims data analysis. The cardiac arrest date was set as day 0. The frequency of survival discharge within 1 year after cardiac arrest was determined. Only administration of candidate drugs limited to 1 month or less after cardiac arrest was included. The medical history and emergency treatment recorded before cardiac arrest and on the day of cardiac arrest were included, respectively.   0  Trazoline  0  Prazosin  0  Isoxsuprine  0  Niacin  0  Flecainide  28  Inositol  0  Nicardipine  98  Procainamide  10  Ifenprodil  0  Nicergoline  0  Propafenone  0  Urapidil  0  Nisoldipine  0  Benidipine  0  Kallidinogenase  0  Nitrangepin  0  Bepridil  0  Quinidine  0  Nitroglycerin  103  Verapamil  134  Guanethidine  0  Nifedipine  0  Mexiletine  2  Disopyramide  32  Nilvadipine  0  Lidocaine  559  Dihydroergocristine  0  Barnidipine  0 Isosorbide nitrate 164 FIGURE 2 | Selection flowchart of candidate drug. First, 165 approved drugs having vasodilator activity were extracted using the drug discovery tool TargetMine. Next, drugs that were not approved in Japan, oral drugs, and external drugs were excluded, and seven drugs were selected that were administered to ≥10 patients within 1 month of cardiac arrest.
Dihydropyridine (DHP) calcium antagonists, such as nicardipine, relax vascular smooth muscles by blocking the membrane voltagedependent L-type calcium channels involved in the influx of extracellular calcium ions. They are used to treat hypertension by relaxing muscles and reducing peripheral vascular resistance. Their main pharmacological actions include coronary and peripheral vasodilator activity, cardiac contractility, and suppression of impulse conduction system. However, cardiac suppression is hardly seen at clinical doses. Nicardipine has excellent organ blood flow maintenance effect and is used in cases of organ failure due to hypertension. Among DHP calcium antagonists, nicardipine has a short onset time and half-life. It is used for hypertensive emergencies and is highly specific for cerebral blood vessels (Takenaka and Handa, 1979).
One common pharmacological effect of the three selected agents (isosorbide dinitrate, nitroglycerine, and nicardipine) is dilation of the coronary artery, which we suggest contributed to the improvement in survival rate after cardiac arrest in this study. Treatment of patients with cardiac arrest involves management of blood pressure; vasoconstrictors such as adrenaline and  noradrenaline are commonly administered for this purpose. However, no sufficient evidence is available to support the effect of vasoconstrictors on the survival and discharge rate of adult patients after resumption of heart rate; excessive administration may lead to decreased blood flow. The prognosis improvement could have resulted from increased oxygen supply to the heart through the dilation of the coronary artery, relief in the heart afterload, and the increase in whole organ blood flow to the heart. In addition, nicardipine has been shown to directly dilate cerebral blood vessels (Takenaka and Handa, 1979) and nitroglycerin has been reported to improve neurologic prognosis after cardiac arrest in animal studies (Chen et al., 2011). Irreversible damage to cranial nerves in post-cardiac arrest syndrome (PCAS), reported in most patients with cardiac arrest, is a very important risk factor for long-term poor prognosis of cardiac arrest patients. Thus, it can be suggested that increased cerebral blood flow, which suppresses irreversible damage to the cranial nerves associated with circulatory failure, also contributed to the improvement of long-term outcomes.
This study has several limitations. First, we could not evaluate the effect of drugs not approved in Japan. Because the JMDC claims database contains only Japanese claim data, we could only include drugs approved in Japan in the analysis. Thus, we may have missed promising drug candidates, which should be considered in future studies. Second, we defined each comorbidity based on the description in the claim data. However, the diagnostic methods and diagnosis criteria could be inconsistent, and, thus, the quality of diagnosis might be inconsistent. Third, the JMDC claims database does not provide some information, such as the cause of cardiac arrest, the quality of cardiopulmonary resuscitation, medication adherence, the dose and duration of drug administration, and clinical laboratory test results. In the studies using propensity scores, all factors affecting treatment allocation should be investigated and included as covariates. However, propensity score matching cannot be used as a substitute to the randomized comparison trials, which can balance out unknown covariates. In future, prospective observational studies should be conducted and information on background factors related to cardiac arrest should be collected.

CONCLUSION
Three drugs (isosorbide dinitrate, nitroglycerine, and nicardipine) were identified in this study as candidate novel therapeutic agents to improve the prognosis of cardiac arrest patients. These results could prove to be valuable in therapeutic drug development for cardiac arrest patients because it is difficult to conduct clinical trials in these patients due to the urgency of their treatment. Moreover, the procedure used for the identification of candidate drugs in the present study is a very useful method that combines multifaceted evaluation using drug discovery tools and claims databases. To confirm the usefulness of the results and method used in this study and to use the three identified drugs for their therapeutic effect in cardiac arrest patients, it is necessary to validate these results in clinical settings.

DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article/ Supplementary Material.

ETHICS STATEMENT
This study was conducted in keeping with the Ministry of Health, Labour, and Welfare's Ethical Guidelines for Epidemiological Research. It was approved by the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital Ethics Committee (No. 1706-022-001) and conformed to the tenets of the Declaration of Helsinki. Since this study was an observational study with anonymized information, with no treatment intervention and no collection of human samples, obtainment of informed consent was exempted.